Abstract:Background: Abnormal mucosal inflammation is a critical risk factor for pathogenesis and progression of colorectal cancer (CRC). As a type of proinflammatory death, pyroptosis can recast a suitable microenvironment to promote tumor growth. However, the potential role of pyroptosis in CRC remains unclear. Methods: A total of 38 pyroptosis-related gene (PRG) expression profiles and clinical information were collected from multiple public datasets. Bioinformatics methods were used to analyze the clinical significance, functional status, immune infiltration, genomic alteration, and drug sensitivity in different subgroups. Whole-genome microarray analysis was performed to analyze the regulation of gut microbiota on the expression of PRGs. Results: Two distinct molecular subtypes were identified and suggested that multilayer PRG alterations were associated with patient clinicopathological features, prognosis, and tumor microenvironment (TME) infiltrating characteristics. Furthermore, we obtained eight PRG signatures by applying differential expression analysis and univariate Cox and Lasso regression analyses. A risk prognosis model was constructed for predicting overall survival (OS) and recurrence-free survival (RFS) based on the PRG signature. There were significant differences in clinical characteristics, 22 immune cells, and immune functions between the high- and low-risk groups. In addition, the PRG signature was significantly associated with the microsatellite instability (MSI), tumor mutation burden (TMB), cancer stem cell (CSC) index, immunotherapeutic characteristics, and chemotherapeutic drug sensitivity. Moreover, the in vitro experiments had shown that Fusobacterium nucleatum ( F.n ) could affect the CASP6 expression, which was associated with the chemoresistance to 5-fluorouracil (5-Fu) in CRC. Conclusion: Our findings provided a foundation for future research targeting pyroptosis and a new insight into the prognosis and immune cell infiltration of CRC, and they suggested that F.n might influence CRC progression through pyroptosis.

Pyroptosis is involved in the inhibitory effect of FL118 on growth and metastasis in colorectal cancer

Role of pyroptosis in cancer cells and clinical applications

Research progress on the effect of pyroptosis on the occurrence, development, invasion and metastasis of colorectal cancer

Pyroptosis: A New Frontier in Cancer

The Role of Pyroptosis in the Progression and Targeted Therapeutic Approaches for Urological Malignancies

Pyroptosis: shedding light on the mechanisms and links with cancers

Pyroptosis Predicts Immunotherapy Outcomes Across Multiple Cancer Types

Pyroptosis Provides New Strategies for the Treatment of Cancer

Pyroptosis: A Promising Target for Lung Cancer Therapy

The Role of Pyroptosis in Gastrointestinal Cancer and Immune Responses to Intestinal Microbial Infection.

Targeted Pyroptosis Is a Potential Therapeutic Strategy for Cancer

Pyroptosis: a new paradigm of cell death for fighting against cancer

Molecular mechanism of pyroptosis and inflammasome activation

The role of pyroptosis in cancer: key components and therapeutic potential

NLRP3 inflammasome-induced pyroptosis in digestive system tumors

Pyroptosis: a new insight into intestinal inflammation and cancer

Pyroptosis in inflammatory diseases and cancer

Role of pyroptosis in inflammation and cancer

Pyroptosis and Its Role in Cancer

Pyroptosis-Related Signature as Potential Biomarkers for Predicting Prognosis and Therapy Response in Colorectal Cancer Patients

Emerging mechanisms of pyroptosis and its therapeutic strategy in cancer